三阴性乳腺癌
紫杉醇
乳腺癌
医学
肿瘤科
内科学
癌症
微管蛋白
癌症治疗
癌症研究
生物
微管
细胞生物学
标识
DOI:10.21007/etd.cghs.2020.0524
摘要
Triple negative breast cancer (TNBC) has aggressive clinical features strongly associated with poorer overall prognosis and higher mortality rates relative to other molecular subtypes. FDA-approved drugs, such as paclitaxel, are effective in treating TNBC. Yet, treatment failure is commonly observed due to the development of acquired chemoresistance, which remains a clinical challenge for TNBC therapy.
科研通智能强力驱动
Strongly Powered by AbleSci AI